Friday, December 5, 2:20pm - 3:20pm (EST)
Description: Syncromune Chief Medical Officer, Urology, and LEGION-100 Phase 2 trial proctor, Dr. Andriole, will provide in-depth insights into SYNC-T SV-102, a novel third-generation combination intratumoral/locoregional immunotherapy designed to elicit a systemic antitumor response in patients with metastatic castration-resistant prostate cancer (mCRPC).
This session will showcase Phase 1 clinical results demonstrating safety, immune activation, and early signs of efficacy, highlighting how SYNC-T SV-102 is reshaping the therapeutic landscape for advanced prostate cancer.
The symposium will also spotlight the LEGION-100 Phase 2 clinical trial, now actively enrolling patients and recruiting clinical trial sites across the U.S. Dr. Andriole will share insights into the trial’s design, scientific rationale, and the opportunity for institutions to partner in evaluating this cutting-edge immunotherapy.
Speaker: Gerald Andriole, M.D., Chief Medical Officer, Urology, Syncromune, Inc.
Time zone
am/pm
24h
Suggestions
Your search did not return any results
Friday, December 5, 2:20pm - 3:20pm (EST)
Confirmed
We've sent a confirmation email to your email address. Be sure to check your junk folder in case you haven't received the confirmation.
Confirmed
We've sent a confirmation email to your email address. Be sure to check your junk folder in case you haven't received the confirmation.
Thank you!
Your changes have been saved. Thanks for keeping us updated.
Limited seats left
Sheraton Phoenix Downtown, Ahwatukee A Room
SUO-CTC & Syncromune, Inc.
